癌症研究
上皮-间质转换
转移
蛋白激酶B
肺癌
生物
MAPK/ERK通路
肿瘤进展
癌变
转移抑制因子
癌症
趋化因子
免疫学
信号转导
医学
肿瘤科
炎症
细胞生物学
遗传学
作者
Shouheng Lin,Qian Zhang,Guohua Huang,Lin Cheng,Peng Li,Di‐Wei Zheng,Simiao Lin,Suna Wang,Qiting Wu,Youguo Long,Baiheng Li,Wei Wei,Pentao Liu,Duanqing Pei,Yangqiu Li,Zhesheng Wen,Shuzhong Cui,Peng Li,Xiaofang Sun,Yi‐Long Wu,Yao Yao
出处
期刊:Oncogene
[Springer Nature]
日期:2021-01-15
卷期号:40 (8): 1476-1489
被引量:47
标识
DOI:10.1038/s41388-020-01605-4
摘要
Myeloid-derived suppressor cells (MDSCs) suppress antitumor immune activities and facilitate cancer progression. Although the concept of immunosuppressive MDSCs is well established, the mechanism that MDSCs regulate non-small cell lung cancer (NSCLC) progression through the paracrine signals is still lacking. Here, we reported that the infiltration of MDSCs within NSCLC tissues was associated with the progression of cancer status, and was positively correlated with the Patient-derived xenograft model establishment, and poor patient prognosis. Intratumoral MDSCs directly promoted NSCLC metastasis and highly expressed chemokines that promote NSCLC cells invasion, including CCL11. CCL11 was capable of activating the AKT and ERK signaling pathways to promote NSCLC metastasis through the epithelial-mesenchymal transition (EMT) process. Moreover, high expression of CCL11 was associated with a poor prognosis in lung cancer as well as other types of cancer. Our findings underscore that MDSCs produce CCL11 to promote NSCLC metastasis via activation of ERK and AKT signaling and induction of EMT, suggesting that the MDSCs-CCL11-ERK/AKT-EMT axis contains potential targets for NSCLC metastasis treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI